In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma.
Developing gene therapy strategies may allow contemporary medicine to reassess its management of solid malignancies. We have demonstrated previously that the wild-type p53 adenovirus (Ad5CMV-p53) suppressed the growth of established tumors of the head and neck. In this paper we develop a microscopic residual model which mimics the postsurgical environment of head and neck cancer patients with advanced disease. Using this squamous cell carcinoma of the head and neck model, we prevented the establishment of tumors in nude mice in which tumor cells had been s.c. implanted by transiently introducing exogenous wild-type p53 via an adenoviral vector 2 days following tumor cell implantation. These effects were vector dose dependent but independent on the endogenous wild-type or mutated p53 status of the cells. Importantly, karyotypically normal and nontumorigenic fibroblast cell lines are inert to the p53 adenovirus treatment. These results pave the ground work for further development of molecular therapy for head and neck cancer and other solid malignancies.
Clayman
G L
GL
Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston 77030.
el-Naggar
A K
AK
Roth
J A
JA
Zhang
W W
WW
Goepfert
H
H
Taylor
D L
DL
Liu
T J
TJ
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D005347:Fibroblasts; D016158:Genes, p53; D015316:Genetic Therapy; D005822:Genetic Vectors; D006258:Head and Neck Neoplasms / Q000628:therapy*; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D014161:Transduction, Genetic; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D016159:Tumor Suppressor Protein p53